Premium
Use of macrolides during pregnancy and the risk of birth defects: a population‐based study
Author(s) -
Bérard Anick,
Sheehy Odile,
Zhao JinPing,
Nordeng Hedvig
Publication year - 2015
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.3900
Subject(s) - medicine , azithromycin , clarithromycin , erythromycin , pregnancy , confounding , obstetrics , penicillin , cohort study , population , relative risk , cohort , gynecology , pediatrics , confidence interval , antibiotics , environmental health , genetics , microbiology and biotechnology , biology , helicobacter pylori
Purpose Macrolides have been linked to the occurrence of congenital heart defects, but findings are inconsistent. We therefore aimed to estimate the risk of major congenital malformations (MCMs) after fetal exposure to macrolides, focusing on cardiac malformations. Methods From the Quebec Pregnancy Cohort (1998–2008), women exposed to a macrolide or penicillin in the first trimester and unexposed women were studied. There were 135 859 pregnancies included; 914 were exposed to azithromycin, 734 to erythromycin, 686 to clarithromycin, and 9106 to penicillin during the first trimester. Cases of MCMs were identified within the first year of life. Results After adjusting for potential confounders, azithromycin (RR = 1.19, 95%CI: 0.98, 1.44; 120 exposed cases), erythromycin (RR = 0.96, 95%CI: 0.74, 1.24; 66 exposed cases) and clarithromycin use (RR = 1.12, 95%CI: 0.99, 1.42; 79 exposed cases) during the first trimester of pregnancy were not statistically significantly associated with the risk of MCMs; no associations were observed for cardiac malformations. Conclusions First trimester exposure to any of the macrolides was not associated with an increased risk of overall MCMs or cardiac malformations specifically. Copyright © 2015 John Wiley & Sons, Ltd.